Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact | 
Explore Technologies



Diagnostic Markers And Targets In Human Heart Failure


Stanford Reference:

03-116


Abstract


The invention provides a method of treating or preventing heart failure or a disease or condition associated with heart failure comprising administering an effective dose of an apelin peptide or APJ receptor ligand to the subject. According to certain embodiments of the invention the apelin peptide is administered chronically. In certain embodiments of the invention the apelin peptide is administered in an amount effective to improve at least one hemodynamic parameter or prognostic variable for heart failure. Clinical conditions associated with heart failure include, but are not limited to, atherosclerosis, restenosis, ischemic cardiovascular diseases, idiopathic or viral cardiomyopathy, and the like.

Applications


  • Diagnosis, prognosis and treatment of heart failure:

    • New pharmacological targets
    • New markers for diagnosis of heart failure and recovery

Advantages


  • The role of these genes in human heart failure has not been previously described.

Innovators & Portfolio



Patent Status



Date Released

 5/28/2019 12:00
 

Licensing Contact


Imelda Oropeza, Senior Licensing Manager, Physcial Sciences
650-725-9039 (Business)
Request Info

97-059 Development of a Regulatable Retroviral-Vector System for Identification of Untranslated Regions of mRNAs
03-321 endothelial derived lipase (EDL) knockout mouse
06-327 Pbx1 knockout mice - (B6.129S-Pbx1tm3.1Mlc/J)

more technologies »

Related Keywords


cardiovascular   LS: molecular diagnostic: biomarker